Oncocyte receives final pricing decision for DetermaRx Molecular Test for lung cancer from CMS

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

DetermaRx has received a pricing decision from Centers for Medicare and Medicaid Services.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.

Login